DUBLIN–(BUSINESS WIRE)–The “Diabetic Nephropathy – Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Report Highlights
This Pharmaceutical and Healthcare latest pipeline guide Diabetic Nephropathy – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Diabetic Nephropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Diabetic Nephropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 4, 18, 16, 25, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 1 molecules, respectively.
Diabetic Nephropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Nephropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Nephropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Nephropathy (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Nephropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
- Introduction
- Diabetic Nephropathy – Overview
- Diabetic Nephropathy – Therapeutics Development
- Diabetic Nephropathy – Therapeutics Assessment
- Diabetic Nephropathy – Companies Involved in Therapeutics Development
- Diabetic Nephropathy – Drug Profiles
- Diabetic Nephropathy – Dormant Projects
- Diabetic Nephropathy – Discontinued Products
- Diabetic Nephropathy – Product Development Milestones
- Appendix
Companies Mentioned
- Aibios Co Ltd
- Algomedix Inc
- Allist Shanghai Pharmaceutical Technology Co Ltd
- Antisense Therapeutics Ltd
- APT Therapeutics Inc
- AptaBio Therapeutics Inc
- Araim Pharmaceuticals Inc
- Astellas Pharma Inc
- AstraZeneca Plc
- Bayer AG
- Betagenon AB
- Bird Rock Bio Inc
- BLR Bio LLC
- Boehringer Ingelheim International GmbH
- CCRP Therapeutics GmbH
- Cellmid Ltd
- Certa Therapeutics Pty Ltd
- ChemoCentryx Inc
- Corbus Pharmaceuticals Inc
- CSL Ltd
- cStem Regeneration Pharmaceutical Co Ltd
- Curacle Co Ltd
- Cyclerion Therapeutics Inc
- Daiichi Sankyo Co Ltd
- Dimerix Bioscience Pty Ltd
- Future Medicine Co Ltd
- GenKyoTex SA
- Gilead Sciences Inc
- Glycadia Inc
- GNI Group Ltd
- Goldfinch Biopharma Inc
- Guangzhou Magpie Pharmaceutical Co Ltd
- Inspyr Therapeutics Inc
- Johnson & Johnson
- Liminal BioSciences Inc
- MediPost Co Ltd
- Merck & Co Inc
- Mesoblast Ltd
- Mitsubishi Tanabe Pharma Corp
- Novartis AG
- Novo Nordisk AS
- Noxxon Pharma AG
- Orbsen Therapeutics Ltd
- Paranta Biosciences Ltd
- PhytoHealth Corp
- ProKidney LLC
- Reata Pharmaceuticals Inc
- Redx Pharma Plc
- Sarfez Pharmaceuticals Inc
- Scohia Pharma Inc
- Serodus ASA
- Sulfateq BV
- Teijin Pharma Ltd
- Theravance Biopharma Inc
- Twoxar Inc
- Vidasym Inc
- ZyVersa Therapeutics Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/cy5g2w
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900